8-K: Tyra Biosciences Reports Positive Clinical Data for TYRA-300 and Provides Corporate Update

Tyra Biosciences announced positive interim clinical results for TYRA-300 in metastatic urothelial cancer, along with other corporate updates including a strengthened leadership team and a strong cash position.

Summary

• Tyra Biosciences reported its third quarter 2024 financial results and provided a corporate update.
• The company announced positive interim clinical proof-of-concept results for TYRA-300 in patients with metastatic urothelial cancer (mUC) from the SURF301 Phase 1/2 study, with 54.5% of patients achieving a confirmed partial response at the 90mg dose.
• An Investigational New Drug (IND) application was cleared for a Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301).
• Doug Warner, MD, was appointed as Chief Medical Officer.
• The company's cash, cash equivalents, and marketable securities totaled $360.1 million as of September 30, 2024.
• Tyra plans to submit an IND for a Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer (NMIBC) by the end of 2024.
• The first patient in the Phase 2 achondroplasia study is expected to be dosed in the first quarter of 2025.
• The company's net loss for the third quarter of 2024 was $24.0 million, compared to $21.2 million for the same period in 2023.
• Research and development expenses for the third quarter of 2024 were $22.7 million, compared to $19.3 million for the same period in 2023.

Sentiment

Score: 8

Explanation: The document is very positive due to the strong clinical data for TYRA-300, the IND clearance for the achondroplasia study, and the company's solid financial position. The appointment of a new CMO also adds to the positive sentiment. However, the increased net loss and R&D expenses are a minor concern.

Positives

• The interim clinical data for TYRA-300 in mUC is very encouraging, showing a high response rate and good safety profile.
• The clearance of the IND for the Phase 2 achondroplasia study is a significant milestone.
• The company has a strong cash position of $360.1 million, which is expected to fund operations through at least 2026.
• The appointment of a new Chief Medical Officer with extensive experience is a positive development for the company's clinical programs.
• The company is advancing multiple clinical programs across different indications.

Negatives

• The company reported a net loss of $24.0 million for the third quarter of 2024, which is an increase compared to the $21.2 million loss in the same period of 2023.
• Research and development expenses increased to $22.7 million in Q3 2024 from $19.3 million in Q3 2023, reflecting increased clinical trial costs.

Risks

• Clinical trial results are preliminary and may not be indicative of final outcomes.
• The company's drug development programs are still in early stages and may not lead to successful products.
• There are risks associated with regulatory approvals and potential delays in clinical trials.
• The company is dependent on third parties for manufacturing and research.
• The company may need to raise additional capital in the future.
• Unstable market and economic conditions could adversely affect the business.

Future Outlook

The company expects its current cash position to fund operations through at least 2026 and plans to expand clinical development of TYRA-300 into NMIBC and initiate the Phase 2 study for achondroplasia in Q1 2025.

Management Comments

• Todd Harris, CEO of TYRA, stated that the TYRA-300 data provides clinical support that an FGFR3 inhibitor designed to be highly selective can deliver meaningful clinical benefit to heavily pretreated patients with cancer.
• The CEO also mentioned that these results allow the company to expand into larger studies for multiple bladder cancer indications, while aiming to achieve best-in-class annualized growth velocity in achondroplasia.

Industry Context

This announcement is significant in the context of the FGFR inhibitor market, as TYRA-300 is designed to be a highly selective FGFR3 inhibitor, potentially avoiding the toxicities associated with pan-FGFR inhibitors. The positive clinical data in mUC and the expansion into achondroplasia and NMIBC position Tyra as a key player in this space.

Comparison to Industry Standards

• The 54.5% partial response rate in mUC patients with TYRA-300 is competitive with other targeted therapies in this space, such as Erdafitinib, which has shown response rates in the 40% range in similar patient populations.
• The focus on selectivity for FGFR3 is a key differentiator, as many existing FGFR inhibitors are pan-inhibitors that can cause significant toxicities.
• The expansion into achondroplasia is a unique approach, as there are limited targeted therapies for this condition, and the company is aiming for best-in-class annualized growth velocity.
• The company's cash position of $360.1 million is strong compared to other clinical-stage biotech companies, providing a runway through at least 2026.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical data and the company's financial position.
• Employees may be encouraged by the company's progress and growth.
• Patients with mUC and achondroplasia may benefit from the development of new treatment options.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will continue dose escalation in Part B of the SURF301 study.
• Tyra plans to submit an IND for a Phase 2 study of TYRA-300 in NMIBC by the end of 2024.
• The first patient in the Phase 2 achondroplasia study (BEACH301) is expected to be dosed in Q1 2025.

Key Dates

Keywords

TYRA-300, FGFR3, Achondroplasia, Metastatic Urothelial Cancer, Clinical Trial, Precision Medicine, Oncology, Biotechnology, IND, Phase 2, SURF301, BEACH301, NMIBC